| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Alpinumisoflavone targets multiple cellular pathways. It represses both the ERK/MAPK and NF-κB pathways, which are key regulators of cell survival, proliferation, and inflammation. It can induce cell death through apoptosis. It also represses LPS-induced nitric oxide (NO) production in RAW264.7 macrophages by inhibiting NF-κB-dependent transcription. It exhibits estrogenic properties.
|
|---|---|
| ln Vitro |
In vitro, Alpinumisoflavone demonstrates significant cytotoxicity against human lung tumor cells, inducing cell death via apoptosis. It shows cytotoxicity against human osteosarcoma cells and induces apoptosis of HL-60 cells through activation of caspase-3 and cleavage of PARP. It also inhibits the proliferation of L1210 leukemia cells and induces cell cycle arrest at the G2/M phase. Its activity against both Gram-negative and Gram-positive bacteria is shown by MIC values ranging from 3.9 to 125 μg/mL.
|
| ln Vivo |
In vivo activity data for Alpinumisoflavone are limited in standard product descriptions. However, it has shown atheroprotective effects, which may result from its ability to upregulate mechanisms that promote HDL-cholesterol and bile acid formation. It also downregulates the mRNA expression of Esr1, a gene associated with cholesterogenesis, and upregulates Cyp7a1, promoting cholesterol conversion to bile acids.
|
| Enzyme Assay |
Non-cellular assays for Alpinumisoflavone are not standardly detailed. Its activity is typically assessed in cell-based assays. However, its antioxidant properties could be evaluated using chemical assays like DPPH or ABTS radical scavenging. Its ability to inhibit NF-κB could be assessed in a cell-free transcription assay.
|
| Cell Assay |
In vitro cellular assays for Alpinumisoflavone are diverse. To study its anticancer effects, various cancer cell lines (e.g., HL-60, lung tumor cells, osteosarcoma) are treated with the compound, and cell viability is measured. Apoptosis is assessed by caspase-3 activity and PARP cleavage. To study its anti-inflammatory effects, RAW264.7 macrophages are treated with Alpinumisoflavone and stimulated with LPS. Nitric oxide production is measured using the Griess assay, and NF-κB activity is analyzed.
|
| Animal Protocol |
In vivo animal studies for Alpinumisoflavone are not extensively detailed in product information. Based on its atheroprotective effects, potential study designs could involve using atherosclerosis-prone mouse models (e.g., ApoE⁻/⁻ mice) to evaluate its impact on lipid profiles and plaque formation. Endpoints would include serum cholesterol levels and aortic lesion analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Alpinumisoflavone are not extensively characterized. As a flavonoid, it is expected to have moderate oral bioavailability, undergoing extensive metabolism, including glucuronidation and sulfation. Its physicochemical properties (MW 336.3) suggest it is a lipophilic compound.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Alpinumisoflavone are not available. As a naturally occurring compound, it may have a moderate safety profile, but comprehensive toxicity studies are not typically provided for research-grade materials. It should be handled with standard laboratory precautions.
|
| References | |
| Additional Infomation |
Alpinumisoflavone are members of the isoflavone family and are a type of metabolite. They have been reported to be found in apple wood, banyan trees, and other organisms with relevant data.
Alpinumisoflavone is a research-grade natural product for laboratory use only and is not approved for clinical use. Its CAS number is 34086-50-5, and its molecular formula is C₂₀H₁₆O₅. Its primary applications include studying anticancer mechanisms, investigating anti-inflammatory pathways (ERK/MAPK and NF-κB), and exploring the pharmacology of natural flavonoids. |
| Molecular Formula |
C20H16O5
|
|---|---|
| Molecular Weight |
336.33804
|
| Exact Mass |
336.099
|
| CAS # |
34086-50-5
|
| PubChem CID |
5490139
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
562.1±50.0 °C at 760 mmHg
|
| Flash Point |
205.8±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.660
|
| LogP |
5.78
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
599
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RQAMSFTXEFSBPK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O5/c1-20(2)8-7-13-15(25-20)9-16-17(18(13)22)19(23)14(10-24-16)11-3-5-12(21)6-4-11/h3-10,21-22H,1-2H3
|
| Chemical Name |
5-hydroxy-7-(4-hydroxyphenyl)-2,2-dimethylpyrano[3,2-g]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~297.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9732 mL | 14.8659 mL | 29.7318 mL | |
| 5 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL | |
| 10 mM | 0.2973 mL | 1.4866 mL | 2.9732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
